# Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)

> **NCT01483053** · PHASE4 · UNKNOWN · sponsor: **Baker Heart and Diabetes Institute** · enrollment: 40 (estimated)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** Agomelatine
- **DRUG:** Escitalopram

## Key facts

- **NCT ID:** NCT01483053
- **Lead sponsor:** Baker Heart and Diabetes Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-12-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01483053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01483053, "Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01483053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*